Compositions and methods for prognosis and treatment of prostate cancer
AssigneeRosetta Genomics Lts
InventorsAyelet Chajut, Shai Rosenwald
Life of this patent
Estimating the term…
Abstract
Described herein are compositions and methods for prognosis and treatment of prostate cancer patients. Specifically the invention relates to microRNA molecules associated with the prognosis of prostate cancer, as well as various nucleic acid molecules relating thereto or derived therefrom.
Claims21
A method for determining a prognosis for prostate cancer in a subject comprising:
- (a) providing a biological sample from the subject;
- (b) determining the expression level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:
- 1-91 and sequences at least about 80% identical thereto from said sample;
- and
- (c) comparing said expression level to a threshold expression level,
- wherein the expression level of any of SEQ ID NOS:
- 1-91 and sequences at least about 80% identical thereto compared to said threshold expression level is indicative of the prognosis of said subject.
A kit for determining a prognosis of a subject with prostate cancer, said kit comprising a forward primer comprising a nucleic acid sequence that is partially complementary to a sequence selected from SEQ ID NO:
- 1-91, to a fragment thereof or to a sequence at least about 80% identical thereto.
A method for treating or preventing a prostate cancer, comprising administering to a subject in need thereof an effective amount of a composition comprising a nucleic acid sequence selected from the group consisting of:
- (a) SEQ ID NOS:
- 1-25, 37-58, 71-74,
- (b) a complementary sequence of SEQ ID NOS:
- 26-36, 59-70, 75-91;
- and
- (c) sequences having at least 80% identity to (a) or (b).
A method for inhibiting the growth or viability of prostate cancer cells comprising increasing, in said cells, the expression level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:
- 1-25, 37-58, 71-74 and sequences having at least 80% identity thereto.
A method for inhibiting the growth or viability of prostate cancer cells comprising inhibiting, in said cells, the expression level of a nucleic acid sequence selected from the group consisting of SEQ ID NOS:
- 26-36, 59-70, 75-91 and sequences having at least 80% identity thereto.
Dependencies are inferred from the claim text.